Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.53 |
| ▸ | NSD2 | O96028 | 5/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.53 |
| ▸ | SETD7 | Q8WTS6 | 4/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.53 |
| ▸ | PCMT1 | P22061 | 2/20 | 0.53 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.53 |
| ▸ | TRDMT1 | O14717 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.53 |
| ▸ | INMT | O95050 | 2/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.53 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.53 |
| ▸ | RNMT | O43148 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.53 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.53 |
| ▸ | FASN | P49327 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489322 | 0.93 | NNMT (0.54) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL28735751 | 0.93 | NNMT (0.54) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL2167317 | 0.93 | NNMT (0.60) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL28374502 | 0.93 | NNMT (0.59) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL16057650 | 0.90 | NNMT (0.57) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL29620377 | 0.83 | NNMT (0.57) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL21853808 | 0.83 | NNMT (0.57) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL22444816 | 0.83 | NNMT (0.64) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL9754 | 0.83 | NNMT (0.64) | NNMTDOT1LNSD2CARM1SETD7 | |
| SCHEMBL29378634 | 0.83 | NNMT (0.64) | NNMTDOT1LNSD2CARM1SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018002520-A1 | USE OF AT LEAST ONE SELENISED COMPOUND TO INCREASE THE ETHANOL CONTENT OF A COMPOSITION AND ALCOHOLIC FERMENTATION PROCESS USING A PARTICULAR SELENISED COMPOUND | METABOLIUM (FR) | 2018-01-04 | — | — | WO | claimed |
| EP-3116511-B1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-111117895-A | Algal lipid compositions and methods of making and using the same | 全技术公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10201559-B2 | Compositions of selenoorganic compounds and methods of use thereof | ALLTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2686416-B1 | COMPOSITIONS AND METHODS FOR SEPARATING, CHARACTERIZING AND ADMINISTERING SOLUBLE SELENOGLYCOPROTEINS | ALLTECH INC (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018002520-A1 | USE OF AT LEAST ONE SELENISED COMPOUND TO INCREASE THE ETHANOL CONTENT OF A COMPOSITION AND ALCOHOLIC FERMENTATION PROCESS USING A PARTICULAR SELENISED COMPOUND | METABOLIUM (FR) | 2018-01-04 | — | — | WO | disclosed |
| US-9833486-B2 | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | ALLTECH, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160113977-A1 | COMPOSITIONS COMPRISING SELENIUM AND USE OF SAME FOR THE TREATMENT AND PREVENTION OF DISEASE OR CONDITIONS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2016-04-28 | — | — | US | disclosed |
| EP-2968404-A1 | COMPOSITIONS COMPRISING SELENIUM AND USE OF SAME FOR THE TREATMENT AND PREVENTION OF DISEASE OR CONDITIONS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | Alltech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20080107755-A1 | Methods and compositions for altering cell function | ALLTECH, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080008692-A1 | Administer sodium selenite with an antioxidant; enhance expression of Lhx8 gene associated with cognitive function; antioxidant is alkylated diphenylamines, N-alkylated phenylenediamines, phenyl- alpha -naphthylamine; Alzheimer's, Pick's disease; promote development of basal forebrain cholinergic neurons | ALLTECH, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080004255-A1 | Methods and compositions for altering cell function | ALLTECH, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| WO-2007127273-A2 | METHODS AND COMPOSITIONS FOR ALTERING CELL FUNCTION | ALLTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070155687-A1 | Methods and compositions for altering cell function | ALLTECH, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070122491-A1 | Methods and compositions for altering cell function | ALLTECH, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| EP-1779857-A1 | Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes | Alltech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1779856-A1 | Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes | Alltech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1779858-A1 | Use of selenium compounds, especially selenium yeasts for altering cognitive function | Alltech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1774972-A1 | Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes | Alltech, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113977-A1 | COMPOSITIONS COMPRISING SELENIUM AND USE OF SAME FOR THE TREATMENT AND PREVENTION OF DISEASE OR CONDITIONS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | CS, GOT2, SHMT2 | NNMT 560/4885DOT1L 3311/4885NSD2 3171/4885 |
| US-10201559-B2 | Compositions of selenoorganic compounds and methods of use thereof | SHMT2, FPGS, MTR | NNMT 234/4885DOT1L 2491/4885NSD2 1210/4885 |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | SHMT2, FPGS, MTR | NNMT 234/4885DOT1L 2491/4885NSD2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.